Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and Prevalence of Human Papillomavirus Infection to Predict Outcomes from HPV-Based Cervical Cancer Screening in Women and People with a Cervix Living with HIV.

Journal of acquired immune deficiency syndromes (1999)·2026
Same author

Alcohol consumption and oral human papillomavirus infection among men living with HIV: a cross-sectional study from the ULACNet 201 trial.

Scientific reports·2026
Same author

Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated With Impaired Health-Related Quality of Life in People With HIV.

Gastro hep advances·2026
Same author

Can switching to doravirine/lamivudine/tenofovir DF halt or reverse INSTI-associated weight gain?

Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada·2026
Same author

Genotype distribution of human papillomavirus (HPV) types in oral gargle specimens among men living with HIV in Mexico, Brazil, and Puerto Rico: A cross-sectional study.

The Journal of infection·2026
Same author

The risk of HIV and HCV transmission in Canadians living with coinfection before, during, and after the COVID pandemic: A prospective cohort study.

Canadian journal of public health = Revue canadienne de sante publique·2026

Related Experiment Video

Updated: Jun 25, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Antiretroviral rounds. Too many options?

Sharon Walmsley, Timothy Wilkin, Graeme Moyle

    AIDS Clinical Care
    |March 4, 2009
    PubMed
    Summary

    Experts disagree on the best next antiretroviral regimen for patients with triple-class resistance and low viremia. This highlights challenges in managing complex HIV treatment.

    Area of Science:

    • Infectious Diseases
    • Virology
    • Pharmacology

    Background:

    • Managing patients with human immunodeficiency virus (HIV) requires careful consideration of antiretroviral therapy (ART).
    • Triple-class resistance, where HIV is resistant to three major classes of antiretroviral drugs, presents a significant treatment challenge.
    • Low viremia in this context may indicate partial treatment response or a need for regimen optimization.

    Observation:

    • Three infectious disease experts were surveyed regarding treatment recommendations.
    • The patient presented with established triple-class resistant HIV infection.
    • The patient exhibited low levels of detectable viremia.

    Findings:

    • Each expert recommended a different antiretroviral regimen for the patient.

    More Related Videos

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
    19:57

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

    Published on: March 30, 2014

    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
    10:29

    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

    Published on: May 9, 2025

    Related Experiment Videos

    Last Updated: Jun 25, 2026

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
    05:46

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

    Published on: April 9, 2014

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
    19:57

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

    Published on: March 30, 2014

    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
    10:29

    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

    Published on: May 9, 2025

  • Discrepancies arose despite standardized clinical guidelines.
  • No consensus was reached among the specialists.

    • Implications:

    • Expert opinion varies significantly in complex HIV treatment scenarios.
    • Optimal management strategies for triple-class resistant HIV require further investigation.
    • Clinical decision-making for refractory HIV may benefit from collaborative approaches or novel therapeutic options.